• Approved formualtions include 3.75mg and 11.25mg pre filled syringes (also see section 8.3.4.2).

• 100 mg , 200 mg Tablets
• Approved for treating moderate to severe symptoms of uterine fibroids in adults of reproductive age in line with NICE
• Commissioning: ICS (adults), NHSE (16-17 year olds)

Prescribing to remain with the specialist until DXA scans have been performed and any necessary action taken.

Prescribing may be transferred to primary care when no further DXA scans are required.

•  200 micrograms of nafarelin base per spray.
•  when used as part of IVF.

• Approved as an option for treating moderate to severe symptoms of uterine fibroids in adults of reproductive age in line with NICE
• Approved as an option for treating symptoms of endometriosis in adults of reproductive age who have had medical or surgical treatment for endometriosis in line with NICE

Prescribing to remain with the specialist until DXA scans have been performed and any necessary action taken.

Prescribing may be transferred to primary care when no further DXA scans are required.

• 0.25mg/0.5ml solution for injection in pre-filled syringe
• For use as an additional option for use in IVF.

• The following goserelin formulations are approved for use 3.6mg & 10.8mg injections (also see section 8.3.4.2). 
• Note: leuprorelin is now substantially less expensive than goserelin

• The following formulations are approved for use in treating precocious puberty:
  
  • Gonapeptyl Depot® 3.75mg injection;
  • Decapeptyl SR®11.25mg injection.
    
    
• Refer to Chapter 8 - Gonadorelin analogues for the treatment of prostate cancer. The following strengths are approved:
  
  • 3mg, 11.25mg and 22.5mg